Clinical and biological assessment in systemic necrotizing vasculitides

Clinical and Experimental Rheumatology

Volumn 24, Issue 2 SUPPL. 41, 2006, Pages

  Mukhtyar, C B ^a   Flossmann, O ^a   Luqmani, Raashid A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Diagnostic imaging; Immunologic tests; Outcome assessment; Severity of illness index; Vasculitis

Indexed keywords

BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; ENDOTHELIAL CELL ANTIBODY; ETANERCEPT; FLUORODEOXYGLUCOSE F 18; NEUTROPHIL CYTOPLASMIC ANTIBODY; THROMBOMODULIN; VON WILLEBRAND FACTOR;

CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DOPPLER ECHOGRAPHY; ECHOGRAPHY; HEMATURIA; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MORBIDITY; MORTALITY; NECROTIZING ARTERITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIODIAGNOSIS; RELAPSE; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; SHORT FORM 36; SYSTEMIC VASCULITIS; VASODILATATION;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BIOLOGICAL MARKERS; BIOPSY; CLINICAL TRIALS; HUMANS; MAGNETIC RESONANCE IMAGING; NECROSIS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; ULTRASONICS; VASCULITIS;

EID: 33745712617     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. WEYAND CM, GORONZY JJ: Medium- and large-vessel vasculitis. N Engl J Med 2003; 349: 160-9.
2. JENNETTE JC, FALK RJ: Small-vessel vasculitis. N Engl J Med 1997; 337: 1512-23.
3. WALTON EW: Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 34: 265-70.
4. BOOTH AD, ALMOND MK, BURNS A et al.: Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-84.
5. DEL BUONO EA, FLINT A: Diagnostic usefulness of nasal biopsy in Wegener's granulomatosis. Hum Pathol 1991; 22: 107-10.
6. DEVANEY KO, TRAVIS WD, HOFFMAN G, LEAVITT R, LEBOVICS R, FAUCI AS: Interpretation of head and neck biopsies in Wegener's granulomatosis. A pathologic study of 126 biopsies in 70 patients. Am J Surg Pathol 1990; 14: 555-64.
7. AASAROD K, BOSTAD L, HAMMERSTROM J, JORSTAD S, IVERSEN BM: Renal histopathology and clinical course in 94 patients with Wegener's granulomatosis. Nephrol Dial Transplant 2001; 16: 953-60.
8. HOFFMAN GS, AHMED AE: Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). Int J Cardiol 1998; 66 (Suppl. 1): S191-4; discussion S195.: S191-S194.
9. DAVIES DJ, MORAN JE, NIALL JF, RYAN GB: Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982; 285: 606.
10. Van der WOUDE FJ, RASMUSSEN N, LOBATTO S et al.: Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985; 1: 425-9.
11. FALK RJ, JENNETTE JC: Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-7.
12. NILES JL, McCLUSKEY RT, AHMAD MF, ARNAOUT MA: Wegener's granulomatosis autoantigen is a novel neutrophil serine proteinase. Blood 1989; 74: 1888-93.
13. SAVIGE J, GILLIS D, BENSON E et al.: International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA). Am J Clin Pathol 1999; 111: 507-13.
14. HAGEN EC, ANDRASSY K, CSERNOK E et al.: Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods 1996; 196: 1-15.
15. SABLE-FOURTASSOU R, COHEN P, MAHR A et al.: Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-8.
16. SINICO RA, DI TOMA L, MAGGIORE U et al.: Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926-35.
17. CHEN M, YU F, ZHANG Y, ZHAO MH: Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J 2005; 81: 723-7.
18. de GROOT K, JAYNE D: What is new in the therapy of ANCA-associated vasculitides? Take home messages from the 12th workshop on ANCA and systemic vasculitides. Clin Nephrol 2005; 64: 480-4.
19. MERKEL PA, POLISSON RP, CHANG Y, SKATES SJ, NILES JL: Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126: 866-73.
20. JAYNE DR, GASKIN G, PUSEY CD, LOCKWOOD CM: ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88: 127-33.
21. SLOT MC, TERVAERT JW, BOOMSMA MM, STEGEMAN CA: Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269-73.
22. SANDERS JS, HUITMA MG, KALLENBERG CG, STEGEMAN CA: Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology (Oxford) 2006.
23. BIRCK R, SCHMITT WH, KAELSCH IA, Van der WOUDE FJ: Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47: 15-23.
24. XIAO H, HEERINGA P, HU P et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-63.
25. LITTLE MA, PUSEY CD, NOURSHARGH S: Intravital microscopy in the study of ANCA-associated systemic vasculitis. Clin Nephrol 2005; 64: 465-70.
26. LUQMANI RA, BACON PA, BEAMAN M et al.: Classical versus non-renal Wegener's granulomatosis. Q J Med 1994; 87: 161-7.
27. HUDSON BG, TRYGGVASON K, SUNDARAMOORTHY M, NEILSON EG: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348: 2543-56.
28. AGNELLO V, ROMAIN PL: Mixed cryoglobulinemia secondary to hepatitis C virus infection. Rheum Dis Clin North Am 1996; 22: 1-21.
29. D'AMICO G, FORNASIERI A: Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis 1995; 25: 361-9.
30. DAUM TE, SPECKS U, COLBY TV et al.: Tracheobronchial involvement in Wegener's granulomatosis. Am J Respir Crit Care Med 1995; 151: 522-6.
31. HARPER SL, LETKO E, SAMSON CM et al.: Wegener's granulomatosis: the relationship between ocular and systemic disease. J Rheumatol 2001; 28: 1025-32.
32. BOOMSMA MM, STEGEMAN CA, van der LEIJ MJ et al.: Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-33.
33. JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349: 36-44.
34. BOOTH AD, JAYNE DR, KHARBANDA RK et al.: Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004; 109: 1718-23.
35. D'CRUZ D, DIRESKENELI H, KHAMASHTA M, HUGHES GR: Lymphocyte activation markers and von Willebrand factor antigen in Wegener's granulomatosis: potential markers for disease activity. J Rheumatol 1999; 26: 103-9.
36. KLOCZKO J, KURYLISZYN-MOSKAL A, BERNACKA K, BIELAWIEC M, CYLWIK B, RADZIWON P: Von Willebrand factor antigen in assessment of vasculitis in patients with connective tissue diseases. Clin Rheumatol 1994; 13: 34-8.
37. STEGEMAN CA, TERVAERT JW, HUITEMA MG, de JONG PE, KALLENBERG CG: Serum levels of soluble adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin in patients with Wegener's granulomatosis. Relationship to disease activity and relevance during followup. Arthritis Rheum 1994; 37: 1228-35.
38. WOYWODT A, STREIBER F, de GROOT K, REGELSBERGER H, HALLER H, HAUBITZ M: Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003; 361: 206-10.
39. LEE KW, LIP GY, TAYEBJEE M, FOSTER W, BLANN AD: Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood 2005; 105: 526-32.
40. ZHANG H, VAKIL V, BRAUNSTEIN M et al.: Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005; 105: 3286-94.
41. de LEEUW K, SANDERS JS, STEGEMAN C, SMIT A, KALLENBERG CG, BIJL M: Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005; 64: 753-9.
42. SCHMITT WH, HEESEN C, CSERNOK E, RAUTMANN A, GROSS WL: Elevated serum levels of soluble interleukin-2 receptor in patients with Wegener's granulomatosis. Association with disease activity. Arthritis Rheum 1992; 35: 1088-96.
43. GUILLEVIN L, MAHR A, CALLARD P et al.: Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84: 313-22.
44. GUILLEVIN L, MAHR A, COHEN P et al.: Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004; 51: 482-7.
45. CACOUB P, SAADOUN D, LIMAL N, SENE D, LIDOVE O, PIETTE JC: PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2005; 52: 911-5.
46. MAZZARO C, ZORAT F, CAIZZI M et al.: Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005; 42: 632-8.
47. MISIANI R, BELLAVITA P, FENILI D et al.: Interferon alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330: 751-6.
48. KERR GS, HALLAHAN CW, GIORDANO J et al.: Takayasu arteritis. Ann Intern Med 1994; 120: 919-29.
49. MARCOS HB, CHOYKE PL: Magnetic resonance angiography of the kidney. Semin Nephrol 2000; 20: 450-5.
50. ANDREWS J, AL NAHHAS A, PENNELL DJ et al.: Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis 2004; 63: 995-1000.
51. BLEY TA, WEIBEN O, UHL M et al.: Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 2005; 52: 2470-7.
52. BLEY TA, WIEBEN O, UHL M, THIEL J, SCHMIDT D, LANGER M: High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol 2005; 184: 283-7.
53. SCHMIDT WA, KRAFT HE, VORPAHL K, VOLKER L, GROMNICA-IHLE EJ: Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997; 337: 1336-42.
54. SCHMIDT WA, BLOCKMANS D: Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2005; 17: 9-15.
55. SCHMIDT WA, GROMNICA-IHLE E: Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology (Oxford) 2002; 41: 46-52.
56. BLOCKMANS D, STROOBANTS S, MAES A, MORTELMANS L: Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000; 108: 246-9.
57. TAWAKOL A, MIGRINO RQ, HOFFMANN U et al.: Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography. J Nucl Cardiol 2005; 12: 294-301.
58. KOBAYASHI Y, ISHII K, ODA K et al.: Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET co-registered with enhanced CT. J Nucl Med 2005; 46: 917-922.
59. WALTER MA, MELZER RA, SCHINDLER C, MULLER-BRAND J, TYNDALL A, NITZSCHE EU: The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005; 32: 674-81.
60. MELLER J, STRUTZ F, SIEFKER U et al.: Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003; 30: 730-6.
61. SCHEEL AK, MELLER J, VOSSHENRICH R et al.: Diagnosis and follow up of aortitis in the elderly. Ann Rheum Dis 2004; 63: 1507-10.
62. BLOCKMANS D, KNOCKAERT D, MAES A et al.: Clinical value of [(18)F]fluoro-deoxyglucose positron emission tomography for patients with fever of unknown origin. Clin Infect Dis 2001; 32: 191-6.
63. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-8.
64. de GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 2461-9.
65. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.
66. LUQMANI RA, EXLEY AR, KITAS GD, BACON PA: Disease assessment and management of the vasculitides. Baillieres Clin Rheumatol 1997; 11: 423-46.
67. STONE JH, HOFFMAN GS, MERKEL PA et al.: A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44: 912-20.
68. LUQMANI R: Evaluation of vasculitis disease activity in Europe. Eur J Intern Med 2001; 12: 401-2.
69. de GROOT K, GROSS WL, HERLYN K, REINHOLD-KELLER E: Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol 2001; 55: 31-8.
70. GUILLEVIN L, LHOTE F, GAYRAUD M et al.: Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75: 17-28.
71. EXLEY AR, BACON PA, LUQMANI RA et al.: Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 1997; 40: 371-80.
72. EXLEY AR, CARRUTHERS DM, LUQMANI RA et al.: Damage occurs early in systemic vasculitis and is an index of outcome. QJM 1997; 90: 391-9.
73. KOUTANTJI M, HARROLD E, LANE SE, PEARCE S, WATTS RA, SCOTT DG: Investigation of quality of life, mood, pain, disability, and disease status in primary systemic vasculitis. Arthritis Rheum 2003; 49: 826-37.
74. HOFFMAN GS, DRUCKER Y, COTCH MF, LOCKER GA, EASLEY K, KWOH K: Wegener's granulomatosis: patient-reported effects of disease on health, function, and income. Arthritis Rheum 1998; 41: 2257-62.
75. McHORNEY CA, WARE JE, Jr, ROGERS W, RACZEK AE, LU JF: The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med Care 1992; 30 (5 Suppl.): MS253-MS265.
76. Design of the Wegener's Granulomatosis Etanercept Trial (WGET): Control Clin Trials 2002; 23: 450-68.
77. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. European Community Study Group on Clinical Trials in Systemic Vasculitis ECSYSVASTRIAL. Clin Exp Immunol 1995; 101 (Suppl. 1): 29-34.
78. SCHMITT WH, HAGEN EC, NEUMANN I, NOWACK R, FLORES-SUAREZ LF, Van der WOUDE FJ: Treatment of refractory Wegener's granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int 2004; 65: 1440-8.
79. ARA J, MIRAPEIX E, ARRIZABALAGA P et al.: Circulating soluble adhesion molecules in ANCA-associated vasculitis. Nephrol Dial Transplant 2001; 16: 276-85.
80. COLL-VINENT B, VILARDELL C, FONT C et al.: Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis 1999; 58: 189-92.
81. NOGUCHI S, NUMANO F, GRAVANIS MB, WILCOX JN: Increased levels of soluble forms of adhesion molecules in Takayasu arteritis. Int J Cardiol 1998; 66 (Suppl. 1): S23-33; discussion S35-6.
82. GOBEL U, EICHHORN J, KETTRITZ R et al.: Disease activity and autoantibodies to endothelial cells in patients with Wegener's granulomatosis. Am J Kidney Dis 1996; 28: 186-94.
83. BOEHME MW, SCHMITT WH, YOUINOU P, STREMMEL WR, GROSS WL: Clinical relevance of elevated serum thrombomodulin and soluble E-selectin in patients with Wegener's granulomatosis and other systemic vasculitides. Am J Med 1996; 101: 387-94.